Advice

following an abbreviated submission:

palonosetron soft capsules (Aloxi®) is accepted for use within NHS Scotland.

Indication under review: prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.

At recommended licensed doses the soft capsule formulation has been shown to be clinically non-inferior to the intravenous formulation and is cost neutral.

SMC has previously accepted palonosetron intravenous injection for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Download detailed advice40KB (PDF)

Download

Medicine details

Medicine name:
palonosetron (Aloxi)
SMC ID:
838/13
Indication:
For the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
Pharmaceutical company
Sinclair IS Pharma
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Accepted
Date advice published
11 February 2013